Emergent to assist in production of US COVID-19 vaccine candidates
The company announces it has been task ordered by BARDA to assist in the US government’s efforts to deliver COVID-19 vaccines.
List view / Grid view
The company announces it has been task ordered by BARDA to assist in the US government’s efforts to deliver COVID-19 vaccines.
Advent announced it has manufactured and delivered the first 4,000 doses of the AZD1222 vaccine candidate for the University of Oxford clinical trial.
Cleaning validation is an important element to cGMP manufacturing to ensure purity, quality, and potency of drug product.
Exploring Operation Warp Speed, the Trump Administration’s program to expedite R&D, manufacturing and distribution of medical countermeasures for COVID-19.
Smita Deshmukh describes the current state of the global drug intermediates market, while suggesting how it will grow in the future.
According to findings, the majority of CMOs in Italy are found in the locations hit worst by COVID-19, meaning the pharma supply chain has been greatly impacted.
In this webinar, Lynne Byers explains how you can continue to keep your manufacturing site operating compliantly with significantly less staff.
A survey has revealed that the majority of adults in the UK believe governments need to work together to develop COVID-19 vaccines and treatments, which if effective, should be used worldwide.
This webinar will address the evaluation of microbiological, environmental monitoring data as well as what would be considered significant differences in data.
According to a new agreement between Mylan and Gilead, the former has the rights to manufacture and distribute remdesivir in 127 countries, a drug being tested to combat COVID-19.
This paper provides scientific guidance as well as a case study on the effect of solvent polarity (ethanol/water proportion) on the levels of extractables.
Experts from the US National Institutes of Health have written a commentary to promote a collaborative approach for the testing, scale-up and distribution of COVID-19 vaccine candidates.
A new report has found that in 2019 the FDA approved 119 new drugs and biologics, but that this is down from 137 in 2018, impacting contract manufacturing organisations.
Researchers have begun research to find how sustainable cold chain delivery systems for a COVID-19 vaccine can be established in resource-poor countries.
CEPI has announced that its funding for the Novavax COVID-19 vaccine candidate will go towards Phase I and Phase II trials as well as manufacturing costs.